GABRD and Alzheimer disease: In validation cohort, GABRD+ carrying pTau217 EVs (p < 0.0001), the distribution of GABRD+ carrying pTau217 EVs (p < 0.0001), the distribution of GPR162+ carrying pTau217 EVs (p < 0.05) and GPR162+ carrying pTau217 EVs (p < 0.05) were significantly associated with the diagnosis of AD vs HC.